IP Library Granted Patent US 8,747,895
Granted Patent B2
US 8,747,895 · App. 11/223,819 · Granted Jun 10, 2014

Orally disintegrating tablets of atomoxetine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,747,895
App. No.
11/223,819
Granted
Jun 10, 2014
Kind
B2
Abstract

A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage form may comprise one or more populations of coated atomoxetine-containing particles (beads, pellets, granules etc.) providing a pre-designed rapid release profile after a predesigned lag-time of about 0 to 6 hours following oral administration.

Claims (42)

1. A multiparticulate pharmaceutical composition comprising:

(a) a plurality of timed, pulsatile-release (TPR) beads, wherein the TPR beads comprise drug-containing particles comprising atomoxetine or a pharmaceutically acceptable salt thereof,

wherein said drug-containing particles are coated with a TPR membrane comprising a blend of a water-insoluble polymer and an enteric polymer.

2. The pharmaceutical composition of claim 1 further comprising:

(b) rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol or a saccharide or a combination thereof, wherein the sugar alcohol or saccharide has an average particle diameter of not more than about 30 μm, and

wherein the pharmaceutical composition is in the form of an orally disintegrating tablet.

3. The pharmaceutical composition of claim 1 , further comprising taste-masked beads comprising IR beads coated with a taste-masking membrane,

wherein said IR beads comprise atomoxetine or a pharmaceutically acceptable salt thereof and said taste-masking membrane comprises a water-insoluble polymer.

4. The pharmaceutical composition of claim 3 , wherein said taste-masked beads and TPR beads are present in said pharmaceutical composition at a ratio of taste-masked beads to TPR beads of from about 30:70 to about 90:10 by weight.

5. The pharmaceutical composition of claim 2 , wherein the ratio of rapidly-dispersing microgranules to TPR beads or the ratio of rapidly-dispersing microgranules to a combination of TPR beads and taste-masked beads is within the range of from about 9:1 to 2:1 by weight, and

wherein said taste-masked beads comprise IR beads coated with a taste-masking membrane, and said IR beads comprise atomoxetine or a pharmaceutically acceptable salt thereof and said taste-masking membrane comprises a water-insoluble polymer.

6. The pharmaceutical composition of claim 5 , wherein said orally disintegrating tablet disintegrates on contact with the saliva in the buccal cavity within about 60 seconds.

7. The pharmaceutical composition of claim 1 , wherein said water insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylate acid copolymers and mixtures thereof.

8. The pharmaceutical composition of claim 3 , wherein said taste-masking membrane comprises a water-insoluble ethylcellulose or polyvinyl acetate and the membrane is present in an amount of about 5% to about 40% based on the total weight of the coated bead.

9. The pharmaceutical composition of claim 1 , wherein said TPR membrane comprises a water-insoluble polymer and an enteric polymer at a weight ratio of from about 10:1 to about 1:1.

10. The pharmaceutical composition of claim 1 , wherein said TPR membrane is present in an amount of about 10% to about 60% based on the total weight of the coated TPR bead.

11. The pharmaceutical composition of claim 1 , wherein said TPR membrane further comprises a plasticizer selected from the group consisting of triacetin, tributyl citrate, tri-ethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil and acetylated mono- and di-glycerides and mixtures thereof.

12. The pharmaceutical composition of claim 1 , wherein said drug-containing particles comprise inert particles coated with atomoxetine or a pharmaceutically acceptable salt thereof in a polymeric binder selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone and mixtures thereof.

13. The pharmaceutical composition of claim 12 , wherein said inert particle is selected from the group consisting of sugar spheres, cellulose spheres, and silicone dioxide spheroids.

14. The pharmaceutical composition of claim 2 , wherein said disintegrant is selected from the group consisting of crosslinked polyvinyl pyrrolidone, crosslinked sodium carboxymethylcellulose, sodium starch glycolate, low-substituted hydroxypropylcellulose and mixtures thereof.

15. The pharmaceutical composition of claim 2 , wherein said sugar alcohol or saccharide is selected from the group consisting of mannitol, xylitol, sorbitol, maltol, lactose, sucrose and mixtures thereof.

16. The pharmaceutical composition of claim 3 , wherein said taste-masked beads release substantially all of the atomoxetine contained in said taste-masked beads within about 2 hours following oral administration.

17. The dosage form of claim 16 wherein said TPR beads release substantially all of the atomoxetine contained in said TPR beads within about 4 hours following a lag-time of approximately 1 to 6 hours following oral administration.

18. The pharmaceutical composition of claim 1 , in the form of a dosage form containing a total of from about 10 mg to 60 mg of atomoxetine.

19. A method for the preparation of multi-particulate pharmaceutical dosage form comprising the steps of:

(a) preparing rapidly-dispersing microgranules by granulating a powder mixture comprising a sugar alcohol or a saccharide or a combination thereof having an average particle diameter of not more than about 30 μm and a disintegrant,

(b) preparing TPR beads by applying to drug-containing particles comprising atomoxetine or a pharmaceutically acceptable salt thereof, a TPR coating comprising a combination of a water-insoluble polymer and an enteric polymer, thereby providing an in-vitro lag-time of about 1 to 6 hours,

(c) optionally, preparing taste-masked beads by coating drug-containing particles with a water-insoluble polymer, thereby providing taste-masking properties,

(d) blending rapidly dispersing microgranules from step (a), TPR beads from step (b) and optionally taste-masked beads from step (c), and

(e) compressing the blend from step (d) to form an orally disintegrating tablet.

20. The method of claim 19 wherein the drug-containing particles are prepared by layering atomoxetine or a pharmaceutically acceptable salt thereof from a polymeric binder solution on inert particles selected from the group consisting of sugar spheres, cellulose spheres, and silicon dioxide spheroids.

21. The method of claim 19 wherein said TPR coating comprises ethylcellulose in combination with hypromellose phthalate.

22. The method of claim 21 wherein ethylcellulose and hypromellose phthalate are present at a weight ratio of from about 10:1 to about 1:1.

23. The method of claim 22 wherein said TPR coating is present in an amount of from about 10% to about 60% based on the total weight of the coated TPR bead.

24. A method for treating a patient which comprises administering to the patient the pharmaceutical composition of claim 1 .

25. The method of claim 24 wherein said patient is a child or adolescent being treated for ADHD.

26. The pharmaceutical composition of claim 1 , wherein said enteric polymer is selected from the group consisting of cellulose acetate phthalate, cellulose acetate succinate, polyvinyl acetate phthalate, hypromellose phthalate, anionic methacrylic acid copolymers and mixtures thereof.

27. The pharmaceutical composition of claim 1 , wherein said TPR membrane provide release of the drug after a lag time of about 1-6 hours following oral administration.

28. The method of claim 19 , wherein the TPR beads provide a lag time of about 1 to 6 hours.

29. The method of claim 19 , wherein the method comprises

(c) preparing taste-masked beads by coating drug-containing particles with a water-insoluble polymer, and

wherein the ratio of TPR beads from step (b) to taste-masked beads of step (c) is about 70/30 to 100/0.

Assignments (6)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAMES 037246/0313, 047807/0967, 053474/0276 Recorded Sep 22, 2020
From: BANK OF MONTREAL, AS COLLATERAL AGENT
To: ADARE PHARMACEUTICALS, INC.; ADARE DEVELOPMENT I, L.P.; ADARE PHARMACEUTICALS USA, INC.
Reel/Frame 053852/0697 →
U.S. PATENT SECURITY AGREEMENT Recorded Dec 8, 2015
From: ADARE PHARMACEUTICALS, INC.
To: BANK OF MONTREAL
Reel/Frame 037246/0313 →
CHANGE OF NAME Recorded Aug 5, 2015
From: APTALIS PHARMATECH, INC.
To: ADARE PHARMACEUTICALS, INC.
Reel/Frame 036283/0261 →
TERMINATION AND RELEASE Recorded Jan 31, 2014
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMA US, INC.; APTALIS PHARMATECH, INC.; APTALIS PHARMA CANADA INC.
Reel/Frame 032149/0111 →
PATENT SECURITY AGREEMENT Recorded Oct 31, 2013
From: APTALIS PHARMA CANADA INC.; APTALIS PHARMA US, INC.; APTALIS PHARMATECH, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 031531/0488 →
RELEASE OF LIEN ON PATENTS Recorded Oct 24, 2013
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: APTALIS PHARMATECH, INC.
Reel/Frame 031494/0925 →